Perindopril Oral Tablet
DrugPerindopril oral tablet morning versus evening
Other names: Coversyl 10 mg
NCT Number: NCT03393715
We assessed the influence of time of administration of ACE inhibitors on circadian blood pressure control in sub Saharan type 2 diabetes patients with stage 1 hypertension over 56 days as first line treatment.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Phase 4
Background: Renin-angiotensin system antagonists represent the mainstay of blood pressure (BP) lowering treatment options in people with diabetes. ACE inhibitors have a long half-life and offer the advantage of a single daily dose, usually empirically taken in the morning.
Objective: We assessed the influence of time of administration of ACE inhibitors on circadian BP control in type 2 diabetes (T2D) patients with stage 1 hypertension.
Methods: Twenty T2D patients (9 being women) with a mean age of 58.7 years, diagnosed with stage 1 of hypertension and naive to BP lowering medications, were included. They were randomly allocated to receive perindopril 10 mg/day as a monotherapy either in the morning or in the evening for 28 days, with crossover without washout period on day 29th and additional 28 days follow-up. A 24-hour ambulatory BP monitoring (ABPM) was performed at baseline, days 28 and 56.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Perindopril oral tablet morning versus evening
Other names: Coversyl 10 mg
Time frame: 56 days
Overall blood pressure control
Time frame: 56 days
Blood pressure drop at night
Yaounde Central Hospital
Other Gov
Acronym: CHRONIC1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04286555
Cardiovascular Diseases, Diabetes
Baltimore, Maryland, United States
View Trial DetailsNCT05144737
Body Weight, Cardiovascular Diseases
Baltimore, Maryland, United States
View Trial DetailsNCT05753436
Cardiovascular Diseases, Diabetes Complications
Cairo, Egypt
View Trial DetailsNCT01818674
Behavior, Behavior, Health
Amman, Jordan
View Trial Details